$AGIO
Agios Pharmaceuticals Inc Stock $agio

$agio Overview Financials Valuation SEC Filings Company Website

2017 Q4 Form 10-Q Financial Statement

#000143922217000009 Filed on November 01, 2017

Income Statement

Concept	2017 Q4	2017 Q3	2016 Q3
Revenue	$9.799M	$11.36M	$8.985M
YoY Change	-56.73%	26.41%	63.96%
Cost Of Revenue		$0.00
YoY Change
Gross Profit		$11.36M
YoY Change
Gross Profit Margin		100.0%
Selling, General & Admin	$22.71M	$17.46M	$11.85M
YoY Change	47.66%	47.34%	19.34%
% of Gross Profit		153.72%
Research & Development	$77.22M	$72.92M	$60.64M
YoY Change	19.39%	20.24%	68.32%
% of Gross Profit		641.99%
Depreciation & Amortization	$1.600M	$1.600M	$1.400M
YoY Change	-5.88%	14.29%	40.0%
% of Gross Profit		14.09%
Operating Expenses	$99.93M	$90.38M	$72.50M
YoY Change	24.82%	24.66%	57.76%
Operating Profit	-$90.13M	-$79.02M	-$63.51M
YoY Change	57.0%	24.41%	56.92%
Interest Expense	$1.850M	$1.880M	$680.0K
YoY Change	101.09%	176.47%	209.09%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$88.29M	-$77.14M	-$62.83M
YoY Change	56.29%	22.78%	56.07%
Income Tax	$0.00		$0.00
% Of Pretax Income
Net Earnings	-$88.29M	-$77.14M	-$62.83M
YoY Change	280.59%	22.76%	56.08%
Net Earnings / Revenue	-901.01%	-679.14%	-699.32%
Basic Earnings Per Share
Diluted Earnings Per Share	-$1.809M	-$1.592M	-$1.630M
COMMON SHARES
Basic Shares Outstanding	48.75M shares	48.39M shares	38.05M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2017 Q4	2017 Q3	2016 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$423.9M	$507.9M	$579.1M
YoY Change	-21.69%	-12.29%	64.35%
Cash & Equivalents	$102.7M	$132.7M	$285.5M
Short-Term Investments	$321.2M	$375.2M	$293.6M
Other Short-Term Assets	$17.50M	$15.30M	$10.30M
YoY Change	69.9%	48.54%	43.06%
Inventory	$0.00
Prepaid Expenses
Receivables	$1.200M	$700.0K
Other Receivables	$2.600M	$4.400M
Total Short-Term Assets	$445.3M	$528.3M	$600.9M
YoY Change	-20.47%	-12.09%	61.69%
LONG-TERM ASSETS
Property, Plant & Equipment	$24.43M	$24.02M	$26.26M
YoY Change	-3.58%	-8.54%	24.3%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$143.8M	$133.8M	$43.50M
YoY Change	345.2%	207.59%	-21.76%
Other Assets	$891.0K	$1.070M	$1.339M
YoY Change	-44.83%	-20.09%	97.49%
Total Long-Term Assets	$169.1M	$158.9M	$71.10M
YoY Change	185.69%	123.48%	-8.17%
TOTAL ASSETS
Total Short-Term Assets	$445.3M	$528.3M	$600.9M
Total Long-Term Assets	$169.1M	$158.9M	$71.10M
Total Assets	$614.4M	$687.2M	$672.0M
YoY Change	-0.76%	2.26%	49.65%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$22.77M	$17.90M	$15.42M
YoY Change	33.09%	16.05%	71.93%
Accrued Expenses	$34.03M	$30.76M	$22.81M
YoY Change	6.34%	34.86%	42.68%
Deferred Revenue	$37.84M
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$94.94M	$88.11M	$78.00M
YoY Change	7.36%	12.96%	56.77%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$144.0M	$149.3M	$192.6M
YoY Change	-16.33%	-22.48%	712.66%
Total Long-Term Liabilities	$144.0M	$149.3M	$192.6M
YoY Change	-16.33%	-22.48%	712.66%
TOTAL LIABILITIES
Total Short-Term Liabilities	$94.94M	$88.11M	$78.00M
Total Long-Term Liabilities	$144.0M	$149.3M	$192.6M
Total Liabilities	$238.9M	$237.4M	$270.6M
YoY Change	-8.3%	-12.27%	268.66%
SHAREHOLDERS EQUITY
Retained Earnings	-$798.1M	-$709.8M	-$426.7M
YoY Change	65.18%	66.35%	74.82%
Common Stock	$1.175B	$1.160B	$828.1M
YoY Change	39.53%	40.09%	33.67%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$375.5M	$449.8M	$401.4M
YoY Change
Total Liabilities & Shareholders Equity	$614.4M	$687.2M	$672.0M
YoY Change	-0.76%	2.26%	49.65%

Cashflow Statement

Concept	2017 Q4	2017 Q3	2016 Q3
OPERATING ACTIVITIES
Net Income	-$88.29M	-$77.14M	-$62.83M
YoY Change	280.59%	22.76%	56.08%
Depreciation, Depletion And Amortization	$1.600M	$1.600M	$1.400M
YoY Change	-5.88%	14.29%	40.0%
Cash From Operating Activities	-$74.40M	-$77.70M	-$49.00M
YoY Change	45.31%	58.57%	97.58%
INVESTING ACTIVITIES
Capital Expenditures	-$1.300M	-$2.000M	-$3.400M
YoY Change	8.33%	-41.18%	3.03%
Acquisitions
YoY Change
Other Investing Activities	$43.10M	$68.40M	-$59.30M
YoY Change	-156.49%	-215.35%	-277.54%
Cash From Investing Activities	$41.90M	$66.40M	-$62.70M
YoY Change	-153.99%	-205.9%	-307.62%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	2.600M	5.300M	163.2M
YoY Change	-35.0%	-96.75%	7318.18%
NET CHANGE
Cash From Operating Activities	-74.40M	-77.70M	-49.00M
Cash From Investing Activities	41.90M	66.40M	-62.70M
Cash From Financing Activities	2.600M	5.300M	163.2M
Net Change In Cash	-29.90M	-6.000M	51.50M
YoY Change	-76.04%	-111.65%	577.63%
FREE CASH FLOW
Cash From Operating Activities	-$74.40M	-$77.70M	-$49.00M
Capital Expenditures	-$1.300M	-$2.000M	-$3.400M
Free Cash Flow	-$73.10M	-$75.70M	-$45.60M
YoY Change	46.2%	66.01%	112.09%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2016Q4	agio	Accrued Research And Development Costs Current AccruedResearchAndDevelopmentCostsCurrent	20266000	USD
CY2017Q3	agio	Accrued Research And Development Costs Current AccruedResearchAndDevelopmentCostsCurrent	16043000	USD
CY2017Q3	agio	Available For Sale Securities Non Current Minimum Liquidating Period AvailableForSaleSecuritiesNonCurrentMinimumLiquidatingPeriod	P12M
CY2016Q4	agio	Collaboration Receivable Duefrom Related Parties Current CollaborationReceivableDuefromRelatedPartiesCurrent	4886000	USD
CY2017Q3	agio	Collaboration Receivable Duefrom Related Parties Current CollaborationReceivableDuefromRelatedPartiesCurrent	3489000	USD
	agio	Increase Decreasein Collaboration Receivable Duefrom Related Parties Current IncreaseDecreaseinCollaborationReceivableDuefromRelatedPartiesCurrent	-43000	USD
	agio	Increase Decreasein Collaboration Receivable Duefrom Related Parties Current IncreaseDecreaseinCollaborationReceivableDuefromRelatedPartiesCurrent	-1397000	USD
	agio	Increase Decreasein Royalty Receivable Duefrom Related Parties Current IncreaseDecreaseinRoyaltyReceivableDuefromRelatedPartiesCurrent	0	USD
	agio	Increase Decreasein Royalty Receivable Duefrom Related Parties Current IncreaseDecreaseinRoyaltyReceivableDuefromRelatedPartiesCurrent	715000	USD
	agio	Proceeds From Stock Options Exercised In Other Current Assets ProceedsFromStockOptionsExercisedInOtherCurrentAssets	0	USD
	agio	Proceeds From Stock Options Exercised In Other Current Assets ProceedsFromStockOptionsExercisedInOtherCurrentAssets	95000	USD
	agio	Public Offering Costs In Other Current Assets PublicOfferingCostsInOtherCurrentAssets	124000	USD
	agio	Public Offering Costs In Other Current Assets PublicOfferingCostsInOtherCurrentAssets	318000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	4444000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-25000	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	124000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	8693000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3347000	USD
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
	dei	Document Period End Date DocumentPeriodEndDate	2017-09-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001439222
CY2017Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	48754289	shares
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	AGIOS PHARMACEUTICALS INC
CY2017Q3	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	859000	USD
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	17106000	USD
CY2016Q4	agio	Royalty Receivable Duefrom Related Parties Current RoyaltyReceivableDuefromRelatedPartiesCurrent	0	USD
CY2017Q3	agio	Royalty Receivable Duefrom Related Parties Current RoyaltyReceivableDuefromRelatedPartiesCurrent	715000	USD
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
CY2017Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	17899000	USD
	dei	Trading Symbol TradingSymbol	AGIO
CY2016Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	3428000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-534000	USD
CY2016Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	32002000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	1591000	USD
CY2017Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	30760000	USD
CY2016Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	476000	USD
CY2017Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	3089000	USD
CY2016Q4	us-gaap	Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-313000	USD
CY2017Q3	us-gaap	Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-515000	USD
CY2016Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	842013000	USD
CY2017Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1160048000	USD
CY2016Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	12143000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	32246000	USD
CY2017Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	12207000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	35128000	USD
CY2016Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5503345	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5503345	shares
CY2017Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5945959	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5945959	shares
CY2016Q4	us-gaap	Assets Assets	619094000	USD
CY2017Q3	us-gaap	Assets Assets	687200000	USD
CY2016Q4	us-gaap	Assets Current AssetsCurrent	559892000	USD
CY2017Q3	us-gaap	Assets Current AssetsCurrent	528307000	USD
CY2016Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	13000	USD
CY2017Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	10000	USD
CY2016Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	326000	USD
CY2017Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	525000	USD
CY2016Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	412810000	USD
CY2017Q3	us-gaap	Available For Sale Securities AvailableForSaleSecurities	508991000	USD
CY2016Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	413123000	USD
CY2017Q3	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	509506000	USD
CY2016Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue	335400000	USD
CY2017Q3	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue	435500000	USD
CY2016Q4	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	380560000	USD
CY2017Q3	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	375187000	USD
CY2016Q4	us-gaap	Available For Sale Securities Noncurrent AvailableForSaleSecuritiesNoncurrent	32250000	USD
CY2017Q3	us-gaap	Available For Sale Securities Noncurrent AvailableForSaleSecuritiesNoncurrent	133804000	USD
CY2016Q4	us-gaap	Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Greater Than Or Equal To One Year AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear	158	Securities
CY2017Q3	us-gaap	Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Greater Than Or Equal To One Year AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear	238	Securities
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	497000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	226000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	71764000	USD
CY2016Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	285502000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	160754000	USD
CY2017Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	132741000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	213738000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-28013000	USD
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000	shares
CY2017Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	42220444	shares
CY2017Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	48617989	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	42220444	shares
CY2017Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	48617989	shares
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	42000	USD
CY2017Q3	us-gaap	Common Stock Value CommonStockValue	49000	USD
CY2016Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-63102000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-141638000	USD
CY2017Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-77002000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-226587000	USD
CY2016Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	3412000	USD
CY2017Q3	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	3586000	USD
CY2016Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	17773000	USD
CY2017Q3	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	15080000	USD
CY2016Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	35913000	USD
CY2017Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	35867000	USD
CY2016Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	154297000	USD
CY2017Q3	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	134202000	USD
	us-gaap	Depreciation Depreciation	3986000	USD
	us-gaap	Depreciation Depreciation	4778000	USD
CY2016Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.63
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-3.72
CY2017Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.59
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-4.94
CY2016Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	11092000	USD
CY2017Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	11273000	USD
CY2017Q3	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	4000000	USD
CY2017Q3	us-gaap	Fair Value Assets Level2 To Level1 Transfers Amount FairValueAssetsLevel2ToLevel1TransfersAmount	10000000	USD
CY2017Q3	us-gaap	Fair Value Liabilities Level1 To Level2 Transfers Amount FairValueLiabilitiesLevel1ToLevel2TransfersAmount	0	USD
CY2017Q3	us-gaap	Fair Value Liabilities Level2 To Level1 Transfers Amount FairValueLiabilitiesLevel2ToLevel1TransfersAmount	0	USD
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	0	USD
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-40000	USD
CY2016Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11854000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	35335000	USD
CY2017Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	17458000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	48411000	USD
	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	-271000	USD
	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	-2558000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1668000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	742000	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	7328000	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-1242000	USD
	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	-2166000	USD
	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	2519000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	185992000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-20141000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2464000	USD
CY2016Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	678000	USD
CY2017Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	1880000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	4279000	USD
CY2016Q4	us-gaap	Liabilities Liabilities	260503000	USD
CY2017Q3	us-gaap	Liabilities Liabilities	237394000	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	619094000	USD
CY2017Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	687200000	USD
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	88433000	USD
CY2017Q3	us-gaap	Liabilities Current LiabilitiesCurrent	88112000	USD
CY2016Q3	us-gaap	License And Services Revenue LicenseAndServicesRevenue	8985000	USD
	us-gaap	License And Services Revenue LicenseAndServicesRevenue	47244000	USD
CY2017Q3	us-gaap	License And Services Revenue LicenseAndServicesRevenue	10643000	USD
	us-gaap	License And Services Revenue LicenseAndServicesRevenue	32497000	USD
CY2016Q3	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	0	USD
	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	0	USD
CY2017Q3	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	0	USD
	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	0	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	165785000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	282521000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-41832000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-99756000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	89785000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-210778000	USD
CY2016Q3	us-gaap	Net Income Loss NetIncomeLoss	-62834000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-141985000	USD
CY2017Q3	us-gaap	Net Income Loss NetIncomeLoss	-77137000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-226385000	USD
CY2016Q3	us-gaap	Operating Expenses OperatingExpenses	72497000	USD
	us-gaap	Operating Expenses OperatingExpenses	190820000	USD
CY2017Q3	us-gaap	Operating Expenses OperatingExpenses	90375000	USD
	us-gaap	Operating Expenses OperatingExpenses	263876000	USD
CY2016Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-63512000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-143576000	USD
CY2017Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-79017000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-230664000	USD
CY2016Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	168000	USD
CY2017Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	355000	USD
CY2016Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1615000	USD
CY2017Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1070000	USD
CY2016Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-268000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	347000	USD
CY2017Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	135000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-202000	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	89000	USD
	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	367587000	USD
CY2016Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	604525000	USD
CY2017Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2017Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2016Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2017Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2016Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	10264000	USD
CY2017Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	15316000	USD
CY2017Q2	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	270200000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	162150000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	270250000	USD
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	3759000	USD
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	12360000	USD
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	334448000	USD
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	508116000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	25337000	USD
CY2017Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	24019000	USD
CY2016Q3	us-gaap	Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax	0	USD
	us-gaap	Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax	0	USD
CY2017Q3	us-gaap	Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax	0	USD
	us-gaap	Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax	0	USD
CY2016Q3	us-gaap	Research And Development Arrangement Contract To Perform For Others Compensation Earned ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned	4038000	USD
	us-gaap	Research And Development Arrangement Contract To Perform For Others Compensation Earned ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned	18754000	USD
CY2017Q3	us-gaap	Research And Development Arrangement Contract To Perform For Others Compensation Earned ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned	1078000	USD
	us-gaap	Research And Development Arrangement Contract To Perform For Others Compensation Earned ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned	6343000	USD
CY2016Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	60643000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	155485000	USD
CY2017Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	72917000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	215465000	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-483151000	USD
CY2017Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-709776000	USD
CY2016Q3	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	8985000	USD
	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	22244000	USD
CY2017Q3	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	10643000	USD
	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	32497000	USD
CY2016Q3	us-gaap	Revenues Revenues	8985000	USD
	us-gaap	Revenues Revenues	47244000	USD
CY2017Q3	us-gaap	Revenues Revenues	11358000	USD
	us-gaap	Revenues Revenues	33212000	USD
CY2016Q3	us-gaap	Royalty Revenue RoyaltyRevenue	0	USD
	us-gaap	Royalty Revenue RoyaltyRevenue	0	USD
CY2017Q3	us-gaap	Royalty Revenue RoyaltyRevenue	715000	USD
	us-gaap	Royalty Revenue RoyaltyRevenue	715000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	35128000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	32246000	USD
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2969761	shares
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	41.87
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	362903	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1494252	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5218880	shares
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5820611	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	46.79
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	48.68
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	5820611	shares
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	48.68
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	19.31
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	72.43
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	50.61
CY2017Q2	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	5808080	shares
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	529618	shares
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	358591000	USD
CY2017Q3	us-gaap	Stockholders Equity StockholdersEquity	449806000	USD
CY2016Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	38548153	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	38124425	shares
CY2017Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	48459424	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	45851203	shares
	us-gaap	Revenue Recognition Multiple Element Arrangements RevenueRecognitionMultipleElementArrangements	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upon the modifications, under the provisions of ASC 605-25, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Multiple Element Arrangements,</font><font style="font-family:inherit;font-size:10pt;"> we identified the remaining deliverables under the modified arrangement, and determined the best estimate of selling price, or BESP, for the undelivered elements as of the modification date. We then allocated the total arrangement consideration, which included the remaining deferred revenue balance at the modification date, any upfront payments received upon modification and other consideration under the modified arrangement that were deemed to be determinable at the modification date, to each unit of accounting relative to our BESP for each unit of accounting. </font></div></div>

Files In Submission

Name	View Source	Status
0001439222-17-000009-index-headers.html	Edgar Link	pending
0001439222-17-000009-index.html	Edgar Link	pending
0001439222-17-000009.txt	Edgar Link	pending
0001439222-17-000009-xbrl.zip	Edgar Link	pending
agio-0930x17x10q.htm	Edgar Link	pending
agio-20170930.xml	Edgar Link	completed
agio-20170930.xsd	Edgar Link	pending
agio-20170930_cal.xml	Edgar Link	unprocessable
agio-20170930_def.xml	Edgar Link	unprocessable
agio-20170930_lab.xml	Edgar Link	unprocessable
agio-20170930_pre.xml	Edgar Link	unprocessable
exhibit31-1x09x30x2017.htm	Edgar Link	pending
exhibit31-2x09x30x2017.htm	Edgar Link	pending
exhibit32-1x09x30x2017.htm	Edgar Link	pending
exhibit32-2x09x30x2017.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AGIO
Agios Pharmaceuticals Inc Stock $agio

2017 Q4 Form 10-Q Financial Statement

#000143922217000009 Filed on November 01, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AGIO Agios Pharmaceuticals Inc Stock $agio

2017 Q4 Form 10-Q Financial Statement

#000143922217000009 Filed on November 01, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AGIO
Agios Pharmaceuticals Inc Stock $agio